Advertisement

NOVEL MEASURES OF LONGITUDINAL CHANGE IN MEDIAL TEMPORAL LOBE SUBREGIONS DISCRIMINATE PRECLINICAL ALZHEIMER’S DISEASE PATIENTS FROM AMYLOID-β NEGATIVE CONTROLS

      As intervention studies in Alzheimer’s disease (AD) move towards preclinical and prodromal target populations, a major challenge has been finding sensitive outcome measures to disease progression at these early stages. We hypothesize that longitudinal change of the medial temporal lobe (MTL) subregions (the sites of earliest tangle pathology) measured by a new and unique approach that accounts for the common confounds (Figure 1) are more sensitive to disease progression at early stages compared to longitudinal cognitive measures.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'